Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages 1-10

  Carus, Andreas ^a   Gurney, Howard ^b   Gebski, Val ^c   Harnett, Paul ^b   Hui, Rina ^b   Kefford, Richard ^b   Wilcken, Nicholas ^b   Ladekarl, Morten ^a   von der Maase, Hans ^d   Donskov, Frede ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Mental Health Center Glostrup   (Denmark)

Author keywords

Lung cancer; Neutrophils; Ovarian cancer; Prognostic factor; Tumour microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN CELL; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; NEUTROPHILIA; OVARY CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

EID: 84882704403     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-189     Document Type: Article

References (41)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
3. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322. 10.1016/j.ccr.2012.02.022, 22439926.
4. Brandau S, Dumitru CA, Lang S. Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol 2013, 35:163-176. 10.1007/s00281-012-0344-6, 23007469.
5. Dumitru CA, Lang S, Brandau S. Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol 2013, 23:141-148. 10.1016/j.semcancer.2013.02.005, 23485549.
6. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 2013, 23:200-207. 10.1016/j.semcancer.2013.02.001, 23403174.
7. Carus A, Ladekarl M, Hager H, Nedergaard BS, Donskov F. Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer. Br J Cancer 2013, 108:2116-2122. 10.1038/bjc.2013.167, 23591202.
8. Carus A, Ladekarl M, Hager H, Pilegaard H, Nielsen PS, Donskov F. Tumor-associated neutrophils and macrophages in non-small cell lung cancer: No immediate impact on patient outcome. Lung Cancer 2013, 81:130-137. 10.1016/j.lungcan.2013.03.003, 23540719.
9. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339:286-291. 10.1126/science.1232227, 3591506, 23329041.
10. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011, 71:2411-2416. 10.1158/0008-5472.CAN-10-2583, 21427354.
11. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999, 80:1763. 10.1038/sj.bjc.6690594, 2363113, 10468293.
12. Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003, 89:1837-1842. 10.1038/sj.bjc.6601366, 2394463, 14612889.
13. Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, Manzione L, Illiano A, Barbera S, Robbiati SF, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005, 6:669-677. 10.1016/S1470-2045(05)70255-2, 16129367.
14. Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Barnes MN. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. Gynecol Oncol 2008, 108:336-341. 10.1016/j.ygyno.2007.10.012, 18006047.
15. Kishida Y, Kawahara M, Teramukai S, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, et al. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03. Br J Cancer 2009, 101:1537-1542. 10.1038/sj.bjc.6605348, 2778518, 19862000.
16. Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, et al. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer 2011, 105:360-365. 10.1038/bjc.2011.256, 3172911, 21750553.
17. Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, Pfistner B, Diehl V, Engert A, German Hodgkin Study G Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol 2005, 23:8003-8011. 10.1200/JCO.2005.205.60, 16204002, German Hodgkin Study G.
18. Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, Papakotoulas P, Agelidou A, Geroyianni A, Agelidou M, et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung cancer (Amsterdam, Netherlands) 2008, 62:356-363.
19. Jang SH, Kim SY, Kim JH, Park S, Hwang YI, Kim DG, Jung KS. Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients. J Cancer Res Clin Oncol 2013, 139:409-417. 10.1007/s00432-012-1341-9, 23124139.
20. Shimizu T, Yokoi T, Tamaki T, Kibata K, Inagaki N, Nomura S. Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer. Oncol Lett 2013, 5:761-767. 3576211, 23426938.
21. Kim JJ, Park JY, Kim DY, Kim JH, Kim YM, Nam JH, Kim YT. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?. Acta Obstet Gynecol Scand 2010, 89:623-628. 10.3109/00016341003674913, 20423275.
22. Delbaldo C, Chatelut E, Re M, Deroussent A, Seronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY, Vassal G. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2006, 12:6073-6078. 10.1158/1078-0432.CCR-05-2596, 17062683.
23. Fracasso PM, Burris H, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007, 13:986-993. 10.1158/1078-0432.CCR-06-1542, 17289894.
24. Donskov F, von Mehren M, Carus A, George S, Casali RG, Li S, Perkins J, Demetri GD. Neutropenia as a biomarker of sunitinib efficacy in patients (Pts) with Gastrointestinal Stromal Tumour (GIST). Eur J Cancer 2011, 47:S135.
25. Donskov F, Carus A, Barrios CH, Escudier B, Li S, Perkins J, Motzer RJ. Neutropenia and thrombocytopenia during treatment as biomarkers of sunitinib efficacy in patients with metastatic Renal Cell Carcinoma (mRCC). Eur J Cancer 2011, 47:S136.
26. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002, 86:1297-1302. 10.1038/sj.bjc.6600139, 2375356, 11953888.
27. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996, 14:2590-2611.
28. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Europn J Cancer (Oxford, England : 1990) 2009, 45:1950-1958.
29. Banerjee S, Rustin G, Paul J, Williams C, Pledge S, Gabra H, Skailes G, Lamont A, Hindley A, Goss G, et al. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol 2013, 24:679-687. 10.1093/annonc/mds494, 23041585.
30. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, Bureau G, Dabouis G, Van Cutsem O, Mommen P, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000, 89:523-533. 10.1002/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO;2-6, 10931451.
31. Ferrigno D, Buccheri G. Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. Monaldi Arch Chest Dis 2003, 59:193-198.
32. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009, 137:425-428. 10.1016/j.jtcvs.2008.05.046, 19185164.
33. Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res 2011, 31:2995-2998.
34. Holgersson G, Sandelin M, Hoye E, Bergstrom S, Henriksson R, Ekman S, Nyman J, Helsing M, Friesland S, Holgersson M, et al. Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer. Med Oncol 2012, 29:3176-3182. 10.1007/s12032-012-0247-3, 22565809.
35. Cetin B, Kaplan MA, Berk V, Ozturk SC, Benekli M, Isikdogan A, Ozkan M, Coskun U, Buyukberber S. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents. Asian Pac J Cancer Prev 2012, 13:1059-1063. 10.7314/APJCP.2012.13.3.1059, 22631638.
36. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European organisation for research and treatment of cancer-Italian sarcoma group-Australasian gastrointestinal trials group study. J Clin Oncol 2005, 23:5795-5804. 10.1200/JCO.2005.11.601, 16110036.
37. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013, 14:141-148. 10.1016/S1470-2045(12)70559-4, 23312463.
38. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006, 24:1997-2005. 10.1200/JCO.2005.03.9594, 16648500.
39. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011, 104:1288-1295. 10.1038/bjc.2011.100, 3078587, 21448173.
40. Maione P, Rossi A, Di Maio M, Gridelli C. Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer?. Lung Cancer (Amsterdam, Netherlands) 2009, 66:8-14.
41. DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 2008, 27:11-18. 10.1007/s10555-007-9100-0, 18066650.